Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Key claim: A phase II trial is evaluating the safety and efficacy of the combination of pacritinib and selinexor in JAK inhibitor-naïve myelofibrosis patients with anemia and thrombocytopenia.
Abstract
This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.
Why this matters
Cytopenic myelofibrosis represents a distinct PMF subpopulation with worse prognosis and limited tolerance for ruxolitinib-based regimens, making upfront pacritinib (the JAKi approved for thrombocytopenic MF) a logical backbone. Combining it with selinexor — which already showed SVR35 benefit added to ruxolitinib in the SENTRY trial — extends the XPO1 + JAKi paradigm into the JAK-naïve cytopenic setting, potentially reshaping first-line strategy for this difficult-to-treat PMF group.